Rocket Pharmaceuticals Inc (RCKT) - Net Assets
Based on the latest financial reports, Rocket Pharmaceuticals Inc (RCKT) has net assets worth $238.04 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($285.41 Million) and total liabilities ($47.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore RCKT total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $238.04 Million |
| % of Total Assets | 83.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | -39.04% |
| 10-Year Change | 278.88% |
| Growth Volatility | 97.74 |
Rocket Pharmaceuticals Inc - Net Assets Trend (2012–2025)
This chart illustrates how Rocket Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Check Rocket Pharmaceuticals Inc (RCKT) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Rocket Pharmaceuticals Inc (2012–2025)
The table below shows the annual net assets of Rocket Pharmaceuticals Inc from 2012 to 2025. For live valuation and market cap data, see RCKT market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $277.22 Million | -40.16% |
| 2024-12-31 | $463.23 Million | -5.96% |
| 2023-12-31 | $492.57 Million | +0.59% |
| 2022-12-31 | $489.69 Million | +7.69% |
| 2021-12-31 | $454.72 Million | -9.69% |
| 2020-12-31 | $503.52 Million | +63.85% |
| 2019-12-31 | $307.30 Million | +58.37% |
| 2018-12-31 | $194.04 Million | +306.24% |
| 2017-12-31 | $47.76 Million | -34.72% |
| 2016-12-31 | $73.17 Million | -32.76% |
| 2015-12-31 | $108.81 Million | +311.05% |
| 2014-12-31 | $-51.56 Million | -32.56% |
| 2013-12-31 | $-38.90 Million | -25.75% |
| 2012-12-31 | $-30.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rocket Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 133034500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.08 Million | 0.39% |
| Other Comprehensive Income | $-31.00K | -0.01% |
| Other Components | $1.72 Billion | 619.51% |
| Total Equity | $277.22 Million | 100.00% |
Rocket Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Rocket Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
$375.71 Million |
|
LH Shopping Centers Leasehold
BK:LHSC
|
$375.90 Million |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
$376.02 Million |
|
BTS Group AB (publ)
ST:BTS-B
|
$376.36 Million |
|
Tande Co Ltd
SHG:600665
|
$375.55 Million |
|
Orion Engineered Carbons SA
NYSE:OEC
|
$375.55 Million |
|
Guangzhou Devotion Therm Tech
SHE:300335
|
$375.53 Million |
|
Marshall Boya ve Vernik Sanayi AS
IS:MRSHL
|
$375.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rocket Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 463,234,000 to 277,221,000, a change of -186,013,000 (-40.2%).
- Net loss of 223,123,000 reduced equity.
- Share repurchases of 67,000 reduced equity.
- Other comprehensive income decreased equity by 97,000.
- Other factors increased equity by 37,274,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-223.12 Million | -80.49% |
| Share Repurchases | $67.00K | -0.02% |
| Other Comprehensive Income | $-97.00K | -0.03% |
| Other Changes | $37.27 Million | +13.45% |
| Total Change | $- | -40.16% |
Book Value vs Market Value Analysis
This analysis compares Rocket Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-14.70 | $3.44 | x |
| 2013-12-31 | $-18.49 | $3.44 | x |
| 2014-12-31 | $-24.51 | $3.44 | x |
| 2015-12-31 | $16.47 | $3.44 | x |
| 2016-12-31 | $10.95 | $3.44 | x |
| 2017-12-31 | $7.06 | $3.44 | x |
| 2018-12-31 | $4.93 | $3.44 | x |
| 2019-12-31 | $6.27 | $3.44 | x |
| 2020-12-31 | $9.09 | $3.44 | x |
| 2021-12-31 | $7.19 | $3.44 | x |
| 2022-12-31 | $7.19 | $3.44 | x |
| 2023-12-31 | $5.86 | $3.44 | x |
| 2024-12-31 | $4.89 | $3.44 | x |
| 2025-12-31 | $2.49 | $3.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rocket Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-80.49%) is below the historical average (-39.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.96 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.73 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.38 Million |
| 2015 | -62.48% | 0.00% | 0.00x | 1.04x | $-78.86 Million |
| 2016 | -58.57% | 0.00% | 0.00x | 1.77x | $-50.17 Million |
| 2017 | -61.76% | 0.00% | 0.00x | 2.13x | $-34.27 Million |
| 2018 | -38.40% | 0.00% | 0.00x | 1.30x | $-93.92 Million |
| 2019 | -27.08% | 0.00% | 0.00x | 1.21x | $-113.96 Million |
| 2020 | -29.13% | 0.00% | 0.00x | 1.17x | $-197.02 Million |
| 2021 | -37.18% | 0.00% | 0.00x | 1.09x | $-214.54 Million |
| 2022 | -45.31% | 0.00% | 0.00x | 1.13x | $-270.83 Million |
| 2023 | -49.86% | 0.00% | 0.00x | 1.15x | $-294.85 Million |
| 2024 | -55.86% | 0.00% | 0.00x | 1.14x | $-305.07 Million |
| 2025 | -80.49% | 0.00% | 0.00x | 1.19x | $-250.85 Million |
Industry Comparison
This section compares Rocket Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $208,279,129
- Average return on equity (ROE) among peers: -35.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rocket Pharmaceuticals Inc (RCKT) | $238.04 Million | 0.00% | 0.20x | $375.63 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $157.42 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $15.00 Million | -36.18% | 1.03x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $5.82 Million | -168.16% | 1.54x | $27.82 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $10.91 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $3.66 Billion |
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading … Read more